Crysvita OverviewBurosumab (INN, trade name Crysvita) known as KRN23 is a human monoclonal antibody designed for the treatment of X-linked hypophosphatemia. Burosumab was approved by the FDA for its intended purpose, in patients aged 1 year and older, on 17 April 2018. The FDA approval fell under both the breakthrough therapy and orphan drug designations. This drug was developed by Ultragenyx and is in a collaborative license agreement with Kyowa Hakko Kirin. References ^ Statement On A ...
Read more Crysvita Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Burosumab
Recent Crysvita Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 10mg/ml
NDC Database Records for Crysvita: (3 results)Sorted by National Drug Code
- 69794-102 Crysvita 10 mg/ml Subcutaneous Injection by Ultragenyx Pharmaceutical Inc.
- 69794-203 Crysvita 20 mg/ml Subcutaneous Injection by Ultragenyx Pharmaceutical Inc.
- 69794-304 Crysvita 30 mg/ml Subcutaneous Injection by Ultragenyx Pharmaceutical Inc.